Xenetic Biosciences
XBIO
22 hedge funds and large institutions have $1.88M invested in Xenetic Biosciences in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
16% more funds holding
Funds holding: 19 → 22 (+3)
6.36% less ownership
Funds ownership: 17.24% → 10.88% (-6.4%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
45% less capital invested
Capital invested by funds: $3.43M → $1.88M (-$1.55M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $355K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$824K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$203K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$92.5K |
| 4 |
VF
Virtu Financial
New York
|
+$72.9K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$70.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.19M |
| 2 |
Two Sigma Investments
New York
|
-$334K |
| 3 |
Renaissance Technologies
New York
|
-$252K |
| 4 |
Two Sigma Advisers
New York
|
-$209K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$21.7K |
XBIO Hedge Fund Activity: Q4 2021 in Review
22 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q4 2021, worth a combined $1.88M — down 45% from $3.43M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new XBIO positions and 5 closed out — a net gain of 3 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $824K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.19M sold.
- 22 institutional investors held Xenetic Biosciences (XBIO) as of Q4 2021, up from 19 in Q3 2021.
- Funds reported $1.88M of Xenetic Biosciences stock for Q4 2021, down 45% quarter-over-quarter.
- 8 funds opened new Xenetic Biosciences positions in Q4 2021 and 5 closed out, a net change of +3 holders.
- The largest Xenetic Biosciences buyer in Q4 2021 was Vanguard Group, an estimated $824K added.
- The largest Xenetic Biosciences seller in Q4 2021 was Armistice Capital, an estimated $1.19M sold.
Based on aggregated 13F filings for Q4 2021.